AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33350222 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Songling Xuemaikang Capsules
Number of subjects: 52
Study 33350222 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Yuntongding Capsules
Number of subjects: 52
Study 33350222 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Danqi Soft Capsules
Number of subjects: 52
Study 34856443 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuum condition
Number of subjects: 271
Study 34856443 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorical condition
Number of subjects: 271
Study 34856443 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 271
Study 33314487 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 621
Study 33314487 — intervention group
Group type: COMPARATOR
Intervention: enalapril
Number of subjects: 621
Study 36257512 — intervention group
Group type: EXPERIMENTAL
Intervention: Rounded shoulder above the DE (SA)
Number of subjects: 50
Study 36257512 — intervention group
Group type: EXPERIMENTAL
Intervention: Hollow chamfer above the DE (CA)
Number of subjects: 50
Study 36257512 — intervention group
Group type: EXPERIMENTAL
Intervention: Butt joint above the DE (BJ)
Number of subjects: 50
Study 36257512 — intervention group
Group type: EXPERIMENTAL
Intervention: Rounded shoulder below the DE (SB)
Number of subjects: 50
Study 36257512 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamfer below the DE (CB)
Number of subjects: 50
Study 33839692 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib plus rituximab
Number of subjects: 0
Study 33839692 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus rituximab
Number of subjects: 0
Study 32350975 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved saline (PS)
Number of subjects: 68
Study 32350975 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free saline (PFS)
Number of subjects: 68
Study 35491963 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g IV with morphine 0.1 mg/kg
Number of subjects: 220
Study 35491963 — intervention group
Group type: COMPARATOR
Intervention: Placebo IV with morphine 0.1 mg/kg
Number of subjects: 220
Study 33838141 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically informed video (n=34)
Number of subjects: 66
Study 33838141 — intervention group
Group type: COMPARATOR
Intervention: Control video (n=32)
Number of subjects: 66
Study 35589575 — intervention group
Group type: COMPARATOR
Intervention: 20 µg hepatitis B vaccine at 0-1-6 month
Number of subjects: 290
Study 35589575 — intervention group
Group type: COMPARATOR
Intervention: 20 µg hepatitis B vaccine at 0-1-2-6 month
Number of subjects: 290
Study 35589575 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 µg hepatitis B vaccine at 0-1-2-6 month
Number of subjects: 290
Study 35026342 — intervention group
Group type: EXPERIMENTAL
Intervention: Vunakizumab 40 mg
Number of subjects: 187
Study 35026342 — intervention group
Group type: EXPERIMENTAL
Intervention: Vunakizumab 80 mg
Number of subjects: 187
Study 35026342 — intervention group
Group type: EXPERIMENTAL
Intervention: Vunakizumab 160 mg
Number of subjects: 187
Study 35026342 — intervention group
Group type: EXPERIMENTAL
Intervention: Vunakizumab 240 mg
Number of subjects: 187
Study 35026342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 34216635 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmaceutical interventions (NPIs) implemented during the Covid-19 pandemic
Number of subjects: 0
Study 33316457 — intervention group
Group type: EXPERIMENTAL
Intervention: PGx test results provided at the beginning of an episode of care
Number of subjects: 2000
Study 33316457 — intervention group
Group type: COMPARATOR
Intervention: PGx test results provided 6 months later
Number of subjects: 2000
Study 33067301 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of wheelchair user-modified upper-body rowing exercise, 30 min three times per week
Number of subjects: 0
Study 33067301 — intervention group
Group type: COMPARATOR
Intervention: Normal lifestyle (control group)
Number of subjects: 0
Study 34202167 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% KGM
Number of subjects: 13
Study 34202167 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% KGM
Number of subjects: 13
Study 34202167 — intervention group
Group type: COMPARATOR
Intervention: 0% KGM (Control)
Number of subjects: 13
Study 34202167 — intervention group
Group type: COMPARATOR
Intervention: 0.4% KGM (Control)
Number of subjects: 13
Study 32465366 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of Care (POC) management of coagulopathy using ROTEM, PFA 200, Multiplate, and 5% albumin solution
Number of subjects: 46
Study 32465366 — intervention group
Group type: COMPARATOR
Intervention: Non-POC management based on anesthesiologist's experience
Number of subjects: 46
Study 33527352 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral-curvature group (n=51)
Number of subjects: 90
Study 33527352 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial-curvature group (n=39)
Number of subjects: 90
Study 35435961 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC-C (35 mg decitabine and 100 mg cedazuridine)
Number of subjects: 133
Study 35435961 — intervention group
Group type: COMPARATOR
Intervention: IV decitabine (20 mg/m2 once daily for the first 5 days of each 28-day cycle)
Number of subjects: 133
Study 35435961 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC-C
Number of subjects: 133
Study 32920476 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioural intervention provided by a mental health nurse practitioner (MHNP)
Number of subjects: 0
Study 32920476 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33818221 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticultural therapy (HT)
Number of subjects: 32
Study 33818221 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 32741499 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT) protocol
Number of subjects: 28
Study 32741499 — intervention group
Group type: COMPARATOR
Intervention: Control Episodic Recent Thinking (ERT) protocol
Number of subjects: 28
Study 35228493 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured Soybean Protein (40 g in 2 dishes for 4 weeks)
Number of subjects: 47
Study 32241819 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee arthroscopy
Number of subjects: 634925
Study 32241819 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder arthroscopy
Number of subjects: 634925
Study 32241819 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist arthroscopy
Number of subjects: 634925
Study 32241819 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow arthroscopy
Number of subjects: 634925
Study 32241819 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip arthroscopy
Number of subjects: 634925
Study 32241819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle arthroscopy
Number of subjects: 634925
Study 32811427 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rabeprazole (20 mg twice daily)
Number of subjects: 73
Study 32811427 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose rabeprazole (20 mg once daily)
Number of subjects: 73
Study 34890455 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (75 IU)
Number of subjects: 48
Study 34890455 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic (control group)
Number of subjects: 48
Study 34760994 — intervention group
Group type: EXPERIMENTAL
Intervention: oscillating positive airway pressure (oPEP)
Number of subjects: 51
Study 34760994 — intervention group
Group type: COMPARATOR
Intervention: autogenic drainage (AD)
Number of subjects: 51
Study 34258833 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM) intervention
Number of subjects: 40
Study 34258833 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to SDM
Number of subjects: 40
Study 34258833 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators of SDM
Number of subjects: 40
Study 34915654 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated caps for occlusal recording
Number of subjects: 12
Study 34915654 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl siloxane occlusal record
Number of subjects: 12
Study 34487151 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradefovir 30 mg
Number of subjects: 240
Study 34487151 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradefovir 45 mg
Number of subjects: 240
Study 34487151 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradefovir 60 mg
Number of subjects: 240
Study 34487151 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradefovir 75 mg
Number of subjects: 240
Study 34487151 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 240
Study 34016045 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate (Group R) - induction dose of 0.2 mg/kg and maintenance dosage of 1.0 mg/kg/h
Number of subjects: 82
Study 34016045 — intervention group
Group type: COMPARATOR
Intervention: Propofol (Group P) - induction dose of 1.5–2.0 mg/kg and maintenance dosage of 3.0–6.0 mg/kg/h
Number of subjects: 82
Study 34016045 — intervention group
Group type: COMPARATOR
Intervention: Propofol (Group P)
Number of subjects: 82
Study 34016045 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate (Group R)
Number of subjects: 82
Study 32386275 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of tomato juice
Number of subjects: 14
Study 32386275 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of tomato juice
Number of subjects: 14
Study 32386275 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice intake
Number of subjects: 14
Study 32386275 — intervention group
Group type: EXPERIMENTAL
Intervention: Low and high amounts of tomato juice
Number of subjects: 14
Study 36167377 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment summary and management recommendations with communication support
Number of subjects: 210
Study 36167377 — intervention group
Group type: COMPARATOR
Intervention: Usual oncology care
Number of subjects: 210
Study 34490696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (FS)
Number of subjects: 120
Study 34490696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate (FF)
Number of subjects: 120
Study 34490696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous ascorbate (FA)
Number of subjects: 120
Study 34490696 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonyl iron (CI)
Number of subjects: 120
Study 34490696 — intervention group
Group type: COMPARATOR
Intervention: All iron salts (FS, FF, FA, CI)
Number of subjects: 120
Study 32056945 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (BCBT)
Number of subjects: 24
Study 32056945 — intervention group
Group type: COMPARATOR
Intervention: Minimally-directive supportive psychotherapy (control)
Number of subjects: 24
Study 35351366 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model based on radiomic features, imaging characteristics, and serum tumor biomarkers.
Number of subjects: 156
Study 33945343 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparoscopy (Group M)
Number of subjects: 46
Study 33945343 — intervention group
Group type: COMPARATOR
Intervention: Standard laparoscopy (Group S)
Number of subjects: 46
Study 35437951 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonertinib (110 mg) under fasting conditions
Number of subjects: 20
Study 35437951 — intervention group
Group type: COMPARATOR
Intervention: Almonertinib (110 mg) under fed conditions
Number of subjects: 20
Study 35437951 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse reactions in fasting group
Number of subjects: 20
Study 35437951 — intervention group
Group type: COMPARATOR
Intervention: Adverse reactions in fed group
Number of subjects: 20
Study 34574456 — intervention group
Group type: EXPERIMENTAL
Intervention: HearWell Design Team
Number of subjects: 12
Study 34574456 — intervention group
Group type: EXPERIMENTAL
Intervention: HearWell
Number of subjects: 12
Study 34574456 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 33571954 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with metastatic UTUC
Number of subjects: 1340
Study 33571954 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with metastatic UTUC
Number of subjects: 1340
Study 33571954 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age in men
Number of subjects: 1340
Study 33571954 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age in women
Number of subjects: 1340
Study 34843964 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved CRT response (CCS)
Number of subjects: 1603
Study 34843964 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved CRT response (LVESVi)
Number of subjects: 1603
Study 34843964 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized CRT response (CCS)
Number of subjects: 1603
Study 34843964 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized CRT response (LVESVi)
Number of subjects: 1603
Study 34843964 — intervention group
Group type: COMPARATOR
Intervention: Worsened CRT response
Number of subjects: 1603
Study 33012643 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic drug approval process video
Number of subjects: 103
Study 33012643 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioequivalence video
Number of subjects: 103
Study 33012643 — intervention group
Group type: COMPARATOR
Intervention: Control video
Number of subjects: 103
Study 32532581 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube introducer with Macintosh laryngoscope
Number of subjects: 52
Study 32532581 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope alone
Number of subjects: 52
Study 34344706 — intervention group
Group type: EXPERIMENTAL
Intervention: OKZ 64 mg every 2 weeks
Number of subjects: 428
Study 34344706 — intervention group
Group type: EXPERIMENTAL
Intervention: OKZ 64 mg every 4 weeks
Number of subjects: 428
Study 34344706 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 428
Study 34605045 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986263 (90 mg)
Number of subjects: 61
Study 34605045 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986263 (45 mg)
Number of subjects: 61
Study 34605045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 33243605 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-gene prognostic signature constructed using LASSO Cox analysis and multivariate Cox analysis in the training set.
Number of subjects: 539
Study 33243605 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group identified by the prognostic signature.
Number of subjects: 539
Study 33243605 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram incorporating risk score and clinical factors.
Number of subjects: 539
Study 35065784 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (2000 mg peanut protein per day for 134 weeks)
Number of subjects: 146
Study 35065784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 35065784 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy
Number of subjects: 146
Study 32295776 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Technology Plus (MT+) intervention consisting of a smartphone self-monitoring application (Lose-It premium), discussion group, SMS text-based support, and Wi-Fi scale.
Number of subjects: 80
Study 32295776 — intervention group
Group type: COMPARATOR
Intervention: Basic Mobile Technology (MT) intervention consisting of a self-monitoring application (Lose-It basic).
Number of subjects: 80
Study 616034075 — intervention group
Group type: EXPERIMENTAL
Intervention: CTA-based strategy for ruling-out acute coronary syndrome (ACS)
Number of subjects: 1735
Study 616034075 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical risk factors (age, sex, tobacco use, diabetes, race)
Number of subjects: 1735
Study 616034075 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest model based on clinical risk factors
Number of subjects: 1735
Study 616034075 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium score
Number of subjects: 1735
Study 34635391 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV vaccine
Number of subjects: 335
Study 34635391 — intervention group
Group type: COMPARATOR
Intervention: No vaccination (control)
Number of subjects: 335
Study 33253816 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-MI (<0.2) imaging with intermittent high-MI impulses (five frames, 1.8 MHz, MI = 1.0–1.2)
Number of subjects: 50
Study 33253816 — intervention group
Group type: COMPARATOR
Intervention: Low-MI (<0.2) imaging alone
Number of subjects: 50
Study 33253816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-MI impulses
Number of subjects: 50
Study 32641012 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily AIH (15, 90s episodes at 10.0% O2 with 60s intervals at 20.9% O2)
Number of subjects: 85
Study 32641012 — intervention group
Group type: COMPARATOR
Intervention: Daily SHAM (15, 90s episodes at 20.9% O2 with 60s intervals at 20.9% O2)
Number of subjects: 85
Study 32641012 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily AIH + WALK (60-min walking practice)
Number of subjects: 85
Study 32641012 — intervention group
Group type: COMPARATOR
Intervention: Daily SHAM + WALK (60-min walking practice)
Number of subjects: 85
Study 32641012 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily AIH and SHAM interventions
Number of subjects: 85
Study 34543890 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal DHA (400 mg/day)
Number of subjects: 1094
Study 34543890 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 1094
Study 32214294 — intervention group
Group type: EXPERIMENTAL
Intervention: SHP + PRF (SHP-N combined with pulsed radiofrequency of the sacral roots S2-4)
Number of subjects: 58
Study 32214294 — intervention group
Group type: EXPERIMENTAL
Intervention: SHP + PRF
Number of subjects: 58
Study 32214294 — intervention group
Group type: COMPARATOR
Intervention: SHP
Number of subjects: 58
Study 34044366 — intervention group
Group type: EXPERIMENTAL
Intervention: VL0 (0% velocity loss)
Number of subjects: 64
Study 34044366 — intervention group
Group type: EXPERIMENTAL
Intervention: VL10 (10% velocity loss)
Number of subjects: 64
Study 34044366 — intervention group
Group type: EXPERIMENTAL
Intervention: VL20 (20% velocity loss)
Number of subjects: 64
Study 34044366 — intervention group
Group type: EXPERIMENTAL
Intervention: VL40 (40% velocity loss)
Number of subjects: 64
Study 35121639 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg
Number of subjects: 500
Study 35121639 — intervention group
Group type: COMPARATOR
Intervention: adalimumab 40 mg
Number of subjects: 500
Study 35121639 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 500
Study 33422811 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin users
Number of subjects: 4328
Study 33422811 — intervention group
Group type: COMPARATOR
Intervention: Non-metformin users
Number of subjects: 4328
Study 32936087 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Cancer e-Support (BCS) program
Number of subjects: 57
Study 34133211 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) followed by surgery and adjuvant S-1 (CSC group)
Number of subjects: 530
Study 34133211 — intervention group
Group type: COMPARATOR
Intervention: Surgery and adjuvant S-1 (SC group)
Number of subjects: 530
Study 35774405 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 70
Study 35774405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 35246565 — intervention group
Group type: EXPERIMENTAL
Intervention: LED‐LLLT (n=20)
Number of subjects: 40
Study 35246565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 40
Study 32803709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-probiotic group (PreProBG, n = 16; 200 g/day yogurt plus 10 g/day inulin+oligofructose)
Number of subjects: 32
Study 32803709 — intervention group
Group type: COMPARATOR
Intervention: Probiotic group (ProBG, n = 16; 200 g/day yogurt only)
Number of subjects: 32
Study 32803709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 32803709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-probiotic group (PreProBG)
Number of subjects: 32
Study 36179982 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPath web-based reproductive health decision support tool
Number of subjects: 456
Study 36179982 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 456
Study 33651675 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN1908-1909
Number of subjects: 73
Study 33651675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 32920614 — intervention group
Group type: COMPARATOR
Intervention: No irrigation after post preparation (G1)
Number of subjects: 50
Study 32920614 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled water activated for 60 s + distilled water (G2)
Number of subjects: 50
Study 32920614 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl 15 s + distilled water (G3)
Number of subjects: 50
Study 32920614 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA + 5.25% NaOCl + distilled water (G4)
Number of subjects: 50
Study 32920614 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% polyacrylic acid + distilled water (G5)
Number of subjects: 50
Study 36604812 — intervention group
Group type: EXPERIMENTAL
Intervention: ATI-450 50-mg oral tablets twice daily
Number of subjects: 100
Study 36604812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33495134 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation)
Number of subjects: 280
Study 33239067 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 9901
Study 33239067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9901